As of today (2024-04-19), the Forward Annual Dividend Yield of Spero Therapeutics is 0.00%.
As of today (2024-04-19), the Trailing Annual Dividend Yield of Spero Therapeutics is 0.00%.
SPRO's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.59 * Ranked among companies with meaningful Forward Dividend Yield % only.
Spero Therapeutics's Dividends per Share for the
three
months ended in Dec. 2023 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison
For the Biotechnology subindustry, Spero Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics Forward Dividend Yield % Distribution
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Forward Dividend Yield % falls into.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Spero Therapeutics Forward Dividend Yield % Related Terms
Thank you for viewing the detailed overview of Spero Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Spero Therapeutics (Spero Therapeutics) Business Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRO has been successfully added to your